ClinicalTrials.Veeva

Menu

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Enrolling
Phase 1

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Treatments

Drug: Azacitidine
Drug: Venetoclax
Drug: BMS-986497

Study type

Interventional

Funder types

Industry

Identifiers

NCT06419634
CA235-0001
2024-519537-29 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Enrollment

105 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • Detectable levels of cluster of differentiation 33 (CD33) expression.
  • Failed alternative therapies with established benefit.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function.

Exclusion criteria

  • Acute Promyelocytic Leukemia.
  • Clinically active central nervous system leukemia.
  • Active malignant solid tumor.
  • Pregnant or breastfeeding.
  • Other protocol-defined inclusion/exclusion criteria apply.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

105 participants in 3 patient groups

Part 1: Dose Escalation BMS-986497 (Monotherapy)
Experimental group
Treatment:
Drug: BMS-986497
Part 2, Cohort A: Dose Expansion BMS-986497 (Combination Therapy)
Experimental group
Treatment:
Drug: BMS-986497
Drug: Azacitidine
Part 2, Cohort B: Dose Expansion BMS-986497 (Triple Combination Therapy)
Experimental group
Treatment:
Drug: BMS-986497
Drug: Venetoclax
Drug: Azacitidine

Trial contacts and locations

15

Loading...

Central trial contact

First line of the email MUST contain NCT # and Site #.; BMS Study Connect Contact Center www.BMSStudyConnect.com

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems